-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diabetes mellitus is a metabolic disease characterized by high blood sugar clinically.
At present, the etiology and pathogenesis have not been fully understood
.
In recent years, with the improvement of people's living standards, the number of diabetic patients in China has increased significantly, and the trend of younger age has become more and more obvious
.
Therefore, it is very important to strengthen the innovative research and development of diabetes-related drugs
.
It is understood that in order to better benefit patients, many pharmaceutical companies in China are actively deploying innovative development of diabetes drugs
.
For example, Yinnuo Pharmaceutical said recently that in order to develop innovative diabetes therapies, the company has completed a US$120 million Series A financing
.
This round of financing will be used for Suparutide's global Phase III clinical trials, the promotion of multiple First-in-Class pipeline products, and the construction of cGMP production bases
.
According to reports, Suparutide (long-acting human-derived GLP-1), an innovative diabetes drug of Yinnuo Medicine, is currently undergoing clinical phase 3 research.
It is also a domestic long-acting human-derived GLP-1 receptor stimulator with independent intellectual property rights.
Agent
.
The characteristic of Supaglutide injection is that it can not only promote the secretion of insulin, but also promote the regeneration of β cells and improve the quality of β cells.
It is a strategy for the treatment of diabetic specimens
.
From a principle point of view, current studies have confirmed that the weakened intestinal effect is one of the pathogenesis factors of type 2 diabetes
.
Decreased secretion of GLP-1 is one of the important factors leading to decreased sensitivity and functional decline of β cells
.
GLP-1, as a peptide hormone that is both secretin and neurotransmitter, plays multiple roles in the body
.
According to the industry, in the face of such huge market demand, as a new generation of human-derived, long-acting GLP-1 receptor agonist, Suparutide is expected to become a domestic human-derived long-acting GLP-1 drug, with a sales scale of tens of billions.
The blue ocean of a new generation of diabetes drugs
.
If suparutide is successfully listed, it will definitely bring benefits to patients
.
It is understood that in addition to the news of Yinnuo Medicine, there is also good news in the diabetes field recently, that is, on December 19, 2021, a diabetes drug with the words "Chengdu Microchip" written on the pill box was officially launched.
.
It is understood that this oral drug called sitaglipta sodium is used to treat type 2 diabetes.
It is an innovative drug independently developed by China.
It is also a PPAR full agonist for insulin resistance that has completed a confirmatory phase III clinical trial.
It has shown good efficacy and safety in Phase III clinical trials
.
According to the industry, the drug is produced based on the raw material and production line of Siglita sodium in Chengdu, and its listing will bring good news to patients with insulin resistance
.
Relevant sources said that sitaglipta sodium has a better curative effect trend in reducing fasting blood sugar and postprandial blood sugar, has a long-lasting blood sugar lowering effect, and has the effects of improving insulin sensitivity and lowering plasma triglycerides
.
In recent years, due to the increasing aging of the population, improvement of living standards and poor life>
.
Faced with the huge market demand for diabetes drugs, many pharmaceutical companies are competing to deploy
.
It is reported that the clinically common diabetes drugs include the following categories: insulin and its analogues, oral hypoglycemic drugs and GLP-1 receptor agonists.
Among them, chemical oral hypoglycemic drugs mainly include sulfonylurea and non-sulfonyl Urea insulin secretion drugs, biguanides, α-glycosidase inhibitors, thiazolidinediones (TZDs), secretin and DPP-4 inhibitors, SGLT-2 inhibitors
.
At present, the etiology and pathogenesis have not been fully understood
.
In recent years, with the improvement of people's living standards, the number of diabetic patients in China has increased significantly, and the trend of younger age has become more and more obvious
.
Therefore, it is very important to strengthen the innovative research and development of diabetes-related drugs
.
It is understood that in order to better benefit patients, many pharmaceutical companies in China are actively deploying innovative development of diabetes drugs
.
For example, Yinnuo Pharmaceutical said recently that in order to develop innovative diabetes therapies, the company has completed a US$120 million Series A financing
.
This round of financing will be used for Suparutide's global Phase III clinical trials, the promotion of multiple First-in-Class pipeline products, and the construction of cGMP production bases
.
According to reports, Suparutide (long-acting human-derived GLP-1), an innovative diabetes drug of Yinnuo Medicine, is currently undergoing clinical phase 3 research.
It is also a domestic long-acting human-derived GLP-1 receptor stimulator with independent intellectual property rights.
Agent
.
The characteristic of Supaglutide injection is that it can not only promote the secretion of insulin, but also promote the regeneration of β cells and improve the quality of β cells.
It is a strategy for the treatment of diabetic specimens
.
From a principle point of view, current studies have confirmed that the weakened intestinal effect is one of the pathogenesis factors of type 2 diabetes
.
Decreased secretion of GLP-1 is one of the important factors leading to decreased sensitivity and functional decline of β cells
.
GLP-1, as a peptide hormone that is both secretin and neurotransmitter, plays multiple roles in the body
.
According to the industry, in the face of such huge market demand, as a new generation of human-derived, long-acting GLP-1 receptor agonist, Suparutide is expected to become a domestic human-derived long-acting GLP-1 drug, with a sales scale of tens of billions.
The blue ocean of a new generation of diabetes drugs
.
If suparutide is successfully listed, it will definitely bring benefits to patients
.
It is understood that in addition to the news of Yinnuo Medicine, there is also good news in the diabetes field recently, that is, on December 19, 2021, a diabetes drug with the words "Chengdu Microchip" written on the pill box was officially launched.
.
It is understood that this oral drug called sitaglipta sodium is used to treat type 2 diabetes.
It is an innovative drug independently developed by China.
It is also a PPAR full agonist for insulin resistance that has completed a confirmatory phase III clinical trial.
It has shown good efficacy and safety in Phase III clinical trials
.
According to the industry, the drug is produced based on the raw material and production line of Siglita sodium in Chengdu, and its listing will bring good news to patients with insulin resistance
.
Relevant sources said that sitaglipta sodium has a better curative effect trend in reducing fasting blood sugar and postprandial blood sugar, has a long-lasting blood sugar lowering effect, and has the effects of improving insulin sensitivity and lowering plasma triglycerides
.
In recent years, due to the increasing aging of the population, improvement of living standards and poor life>
.
Faced with the huge market demand for diabetes drugs, many pharmaceutical companies are competing to deploy
.
It is reported that the clinically common diabetes drugs include the following categories: insulin and its analogues, oral hypoglycemic drugs and GLP-1 receptor agonists.
Among them, chemical oral hypoglycemic drugs mainly include sulfonylurea and non-sulfonyl Urea insulin secretion drugs, biguanides, α-glycosidase inhibitors, thiazolidinediones (TZDs), secretin and DPP-4 inhibitors, SGLT-2 inhibitors
.
